| - |
Dulaglutide |
Trulicity® |
As monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Dulaglutide is indicated as an add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
Rapid review complete |
29th April 2015 |
 |
| - |
Naloxegel |
Moventig® |
Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). |
Rapid Review Complete |
13th April 2015 |
|
| - |
Obinutuzumab |
Gazyvaro® |
In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy. |
Assessment process complete |
2nd April 2015 |
|
